Building a Genetics Engine to Crack the Target Bottleneck

Regeneron's Regeneron Genetics Center (RGC) is leveraging unprecedented scale and AI-driven analytics to transform drug discovery, with a focus on human genetics as a primary success driver. The guest, Aris Barris, reveals that RGC has moved from sequencing hundreds of thousands to targeting 50–100 million people, integrating genomics, proteomics, and imaging data at population scale. This massive infrastructure—backed by deep AI integration—enables the company to turn genetic discoveries into therapeutic programs at a rate of 10 new programs per year, accelerating the path from data to clinical development. What’s more, Barris argues that human genetics evidence increases the probability of clinical success by four to five times compared to traditional approaches, making it a 'game-changing' competitive advantage. Despite growing competition, Regeneron’s edge lies in its scale, analytical depth, and culture of rapid translation—where discoveries trigger immediate investment and development, not bureaucratic delays. The episode underscores a paradigm shift: drug development is no longer just about chemistry or biology, but about data infrastructure and AI-enabled interpretation. Regeneron’s ability to process millions of data points across genomics, proteomics, and health outcomes allows for predictive modeling of disease risk and therapeutic response. This isn’t just faster R&D—it’s fundamentally different.